Survival benefits of antiretroviral therapy in Brazil: a model-based analysis
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2016 |
| Outros Autores: | , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/29305 |
Resumo: | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil. |
| id |
CRUZ_fdf2439f1603592764ba50bcd9569009 |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/29305 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Luz, Paula M.Girouard, Michael P.Grinsztejn, BeatrizFreedberg, Kenneth A.Veloso, Valdiléa G.Losina, ElenaStruchiner, Claudio J.MacLean, Rachel L.Parker, Robert A.Paltiel, A. DavidWalensky, Rochelle P.2018-10-03T18:48:47Z2018-10-03T18:48:47Z2016LUZ, P. M. et al. Survival benefits of antiretroviral therapy in Brazil: a model-based analysis. Journal of the International AIDS Society, v. 19, n. 1, p. 1-11, 2016.1758-2652https://www.arca.fiocruz.br/handle/icict/2930510.7448/IAS.19.1.20623engSurvival benefits of antiretroviral therapy in Brazil: a model-based analysisinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleFundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.Medical Practice Evaluation Center, Massachusetts General Hospital Boston, MA, USA./ Division of General Internal Medicine, Massachusetts General Hospital Boston, MA, USA.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.Medical Practice Evaluation Center, Massachusetts General Hospital Boston, MA, USA / Division of General Internal Medicine, Massachusetts General Hospital Boston, MA, USA / Division of Infectious Disease, Massachusetts General Hospital Boston, MA, USA / Harvard University Center for AIDS Research, Harvard Medical School Boston, MA, USA / Department of Epidemiology, Boston University School of Public Health Boston, MA, USA / Department of Health Policy and Management, Harvard School of Public Health Boston, MA, USA.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.Medical Practice Evaluation Center, Massachusetts General Hospital Boston, MA, USA / Harvard University Center for AIDS Research, Harvard Medical School Boston, MA, USA / Department of Orthopedic Surgery, Brigham and Women's Hospital Boston, MA, USA / Department of Biostatistics, Boston University School of Public Health Boston, MA, USA.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.Medical Practice Evaluation Center, Massachusetts General Hospital Boston, MA, USA./ Division of General Internal Medicine, Massachusetts General Hospital Boston, MA, USA.Medical Practice Evaluation Center, Massachusetts General Hospital Boston, MA, USA./ Harvard University Center for AIDS Research, Harvard Medical School Boston, MA, USA / Biostatistics Center, Massachusetts General Hospital Boston, MA, USA.Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA.Medical Practice Evaluation Center, Massachusetts General Hospital Boston, MA, USA./ Division of General Internal Medicine, Massachusetts General Hospital Boston, MA, USA / Division of Infectious Disease, Massachusetts General Hospital Boston, MA, USA / Harvard University Center for AIDS Research, Harvard Medical School Boston, MA, USA / Division of Infectious Disease, Brigham and Women's Hospital Boston, MA, USA.Objective: In Brazil, universal provision of antiretroviral therapy (ART) has been guaranteed free of charge to eligible HIV-positive patients since December 1996. We sought to quantify the survival benefits of ART attributable to this programme. Methods: We used a previously published microsimulation model of HIV disease and treatment (CEPAC-International) and data from Brazil to estimate life expectancy increase for HIV-positive patients initiating ART in Brazil. We divided the period of 1997 to 2014 into six eras reflecting increased drug regimen efficacy, regimen availability and era-specific mean CD4 count at ART initiation. Patients were simulated first without ART and then with ART. The 2014-censored and lifetime survival benefits attributable to ART in each era were calculated as the product of the number of patients initiating ART in a given era and the increase in life expectancy attributable to ART in that era. Results: In total, we estimated that 598,741 individuals initiated ART. Projected life expectancy increased from 2.7, 3.3, 4.1, 4.9, 5.5 and 7.1 years without ART to 11.0, 17.5, 20.7, 23.0, 25.3, and 27.0 years with ART in Eras 1 through 6, respectively. Of the total projected lifetime survival benefit of 9.3 million life-years, 16% (or 1.5 million life-years) has been realized as of December 2014. Conclusions: Provision of ART through a national programme has led to dramatic survival benefits in Brazil, the majority of which are still to be realized. Improvements in initial and subsequent ART regimens and higher CD4 counts at ART initiation have contributed to these increasing benefits.BrazilHIVLatin AmericaHighly active antiretroviral therapyModellingSurvivalinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83099https://www.arca.fiocruz.br/bitstream/icict/29305/1/license.txt586c046dcfeef936e32f0323bb9a47c0MD51ORIGINALSurvival benefits of antiretroviral therapy in Brazil_Paula_Luz_etal_INI_Lapclin-AIDS_2016.pdfSurvival benefits of antiretroviral therapy in Brazil_Paula_Luz_etal_INI_Lapclin-AIDS_2016.pdfapplication/pdf443082https://www.arca.fiocruz.br/bitstream/icict/29305/2/Survival%20benefits%20of%20antiretroviral%20therapy%20in%20Brazil_Paula_Luz_etal_INI_Lapclin-AIDS_2016.pdfbb72dbf36246c5ce5a3ca14cc9242617MD52TEXTSurvival benefits of antiretroviral therapy in Brazil_Paula_Luz_etal_INI_Lapclin-AIDS_2016.pdf.txtSurvival benefits of antiretroviral therapy in Brazil_Paula_Luz_etal_INI_Lapclin-AIDS_2016.pdf.txtExtracted texttext/plain49823https://www.arca.fiocruz.br/bitstream/icict/29305/3/Survival%20benefits%20of%20antiretroviral%20therapy%20in%20Brazil_Paula_Luz_etal_INI_Lapclin-AIDS_2016.pdf.txt5d6e0cc5c1eb3dd8d4e6d8b7e03b1084MD53icict/293052023-10-25 22:22:53.471oai:www.arca.fiocruz.br:icict/29305Q0VTU8ODTyBOw4NPIEVYQ0xVU0lWQSBERSBESVJFSVRPUyBBVVRPUkFJUw0KDQpGw6FiaW8gTWFycXVlcywgQ1BGOiAxMTMuMTg3Ljg1Ny00MCwgdmluY3VsYWRvIGEgSU5JIC0gSW5zdGl0dXRvIE5hY2lvbmFsIGRlIEluZmVjdG9sb2dpYSBFdmFuZHJvIENoYWdhcwoKQW8gYWNlaXRhciBvcyBURVJNT1MgZSBDT05EScOHw5VFUyBkZXN0YSBDRVNTw4NPLCBvIEFVVE9SIGUvb3UgVElUVUxBUiBkZSBkaXJlaXRvcwphdXRvcmFpcyBzb2JyZSBhIE9CUkEgZGUgcXVlIHRyYXRhIGVzdGUgZG9jdW1lbnRvOgoKKDEpIENFREUgZSBUUkFOU0ZFUkUsIHRvdGFsIGUgZ3JhdHVpdGFtZW50ZSwgw6AgRklPQ1JVWiAtIEZVTkRBw4fDg08gT1NXQUxETyBDUlVaLCBlbQpjYXLDoXRlciBwZXJtYW5lbnRlLCBpcnJldm9nw6F2ZWwgZSBOw4NPIEVYQ0xVU0lWTywgdG9kb3Mgb3MgZGlyZWl0b3MgcGF0cmltb25pYWlzIE7Dg08KQ09NRVJDSUFJUyBkZSB1dGlsaXphw6fDo28gZGEgT0JSQSBhcnTDrXN0aWNhIGUvb3UgY2llbnTDrWZpY2EgaW5kaWNhZGEgYWNpbWEsIGluY2x1c2l2ZSBvcyBkaXJlaXRvcwpkZSB2b3ogZSBpbWFnZW0gdmluY3VsYWRvcyDDoCBPQlJBLCBkdXJhbnRlIHRvZG8gbyBwcmF6byBkZSBkdXJhw6fDo28gZG9zIGRpcmVpdG9zIGF1dG9yYWlzLCBlbQpxdWFscXVlciBpZGlvbWEgZSBlbSB0b2RvcyBvcyBwYcOtc2VzOwoKKDIpIEFDRUlUQSBxdWUgYSBjZXNzw6NvIHRvdGFsIG7Do28gZXhjbHVzaXZhLCBwZXJtYW5lbnRlIGUgaXJyZXZvZ8OhdmVsIGRvcyBkaXJlaXRvcyBhdXRvcmFpcwpwYXRyaW1vbmlhaXMgbsOjbyBjb21lcmNpYWlzIGRlIHV0aWxpemHDp8OjbyBkZSBxdWUgdHJhdGEgZXN0ZSBkb2N1bWVudG8gaW5jbHVpLCBleGVtcGxpZmljYXRpdmFtZW50ZSwKb3MgZGlyZWl0b3MgZGUgZGlzcG9uaWJpbGl6YcOnw6NvIGUgY29tdW5pY2HDp8OjbyBww7pibGljYSBkYSBPQlJBLCBlbSBxdWFscXVlciBtZWlvIG91IHZlw61jdWxvLAppbmNsdXNpdmUgZW0gUmVwb3NpdMOzcmlvcyBEaWdpdGFpcywgYmVtIGNvbW8gb3MgZGlyZWl0b3MgZGUgcmVwcm9kdcOnw6NvLCBleGliacOnw6NvLCBleGVjdcOnw6NvLApkZWNsYW1hw6fDo28sIHJlY2l0YcOnw6NvLCBleHBvc2nDp8OjbywgYXJxdWl2YW1lbnRvLCBpbmNsdXPDo28gZW0gYmFuY28gZGUgZGFkb3MsIHByZXNlcnZhw6fDo28sIGRpZnVzw6NvLApkaXN0cmlidWnDp8OjbywgZGl2dWxnYcOnw6NvLCBlbXByw6lzdGltbywgdHJhZHXDp8OjbywgZHVibGFnZW0sIGxlZ2VuZGFnZW0sIGluY2x1c8OjbyBlbSBub3ZhcyBvYnJhcyBvdQpjb2xldMOibmVhcywgcmV1dGlsaXphw6fDo28sIGVkacOnw6NvLCBwcm9kdcOnw6NvIGRlIG1hdGVyaWFsIGRpZMOhdGljbyBlIGN1cnNvcyBvdSBxdWFscXVlciBmb3JtYSBkZQp1dGlsaXphw6fDo28gbsOjbyBjb21lcmNpYWw7CgooMykgUkVDT05IRUNFIHF1ZSBhIGNlc3PDo28gYXF1aSBlc3BlY2lmaWNhZGEgY29uY2VkZSDDoCBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPCkNSVVogbyBkaXJlaXRvIGRlIGF1dG9yaXphciBxdWFscXVlciBwZXNzb2Eg4oCTIGbDrXNpY2Egb3UganVyw61kaWNhLCBww7pibGljYSBvdSBwcml2YWRhLCBuYWNpb25hbCBvdQplc3RyYW5nZWlyYSDigJMgYSBhY2Vzc2FyIGUgdXRpbGl6YXIgYW1wbGFtZW50ZSBhIE9CUkEsIHNlbSBleGNsdXNpdmlkYWRlLCBwYXJhIHF1YWlzcXVlcgpmaW5hbGlkYWRlcyBuw6NvIGNvbWVyY2lhaXM7CgooNCkgREVDTEFSQSBxdWUgYSBvYnJhIMOpIGNyaWHDp8OjbyBvcmlnaW5hbCBlIHF1ZSDDqSBvIHRpdHVsYXIgZG9zIGRpcmVpdG9zIGFxdWkgY2VkaWRvcyBlIGF1dG9yaXphZG9zLApyZXNwb25zYWJpbGl6YW5kby1zZSBpbnRlZ3JhbG1lbnRlIHBlbG8gY29udGXDumRvIGUgb3V0cm9zIGVsZW1lbnRvcyBxdWUgZmF6ZW0gcGFydGUgZGEgT0JSQSwKaW5jbHVzaXZlIG9zIGRpcmVpdG9zIGRlIHZveiBlIGltYWdlbSB2aW5jdWxhZG9zIMOgIE9CUkEsIG9icmlnYW5kby1zZSBhIGluZGVuaXphciB0ZXJjZWlyb3MgcG9yCmRhbm9zLCBiZW0gY29tbyBpbmRlbml6YXIgZSByZXNzYXJjaXIgYSBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPIENSVVogZGUKZXZlbnR1YWlzIGRlc3Blc2FzIHF1ZSB2aWVyZW0gYSBzdXBvcnRhciwgZW0gcmF6w6NvIGRlIHF1YWxxdWVyIG9mZW5zYSBhIGRpcmVpdG9zIGF1dG9yYWlzIG91CmRpcmVpdG9zIGRlIHZveiBvdSBpbWFnZW0sIHByaW5jaXBhbG1lbnRlIG5vIHF1ZSBkaXogcmVzcGVpdG8gYSBwbMOhZ2lvIGUgdmlvbGHDp8O1ZXMgZGUgZGlyZWl0b3M7CgooNSkgQUZJUk1BIHF1ZSBjb25oZWNlIGEgUG9sw610aWNhIEluc3RpdHVjaW9uYWwgZGUgQWNlc3NvIEFiZXJ0byBkYSBGSU9DUlVaIC0gRlVOREHDh8ODTwpPU1dBTERPIENSVVogZSBhcyBkaXJldHJpemVzIHBhcmEgbyBmdW5jaW9uYW1lbnRvIGRvIHJlcG9zaXTDs3JpbyBpbnN0aXR1Y2lvbmFsIEFSQ0EuCgpBIFBvbMOtdGljYSBJbnN0aXR1Y2lvbmFsIGRlIEFjZXNzbyBBYmVydG8gZGEgRklPQ1JVWiAtIEZVTkRBw4fDg08gT1NXQUxETyBDUlVaIHJlc2VydmEKZXhjbHVzaXZhbWVudGUgYW8gQVVUT1Igb3MgZGlyZWl0b3MgbW9yYWlzIGUgb3MgdXNvcyBjb21lcmNpYWlzIHNvYnJlIGFzIG9icmFzIGRlIHN1YSBhdXRvcmlhCmUvb3UgdGl0dWxhcmlkYWRlLCBzZW5kbyBvcyB0ZXJjZWlyb3MgdXN1w6FyaW9zIHJlc3BvbnPDoXZlaXMgcGVsYSBhdHJpYnVpw6fDo28gZGUgYXV0b3JpYSBlIG1hbnV0ZW7Dp8OjbwpkYSBpbnRlZ3JpZGFkZSBkYSBPQlJBIGVtIHF1YWxxdWVyIHV0aWxpemHDp8Ojby4KCkEgUG9sw610aWNhIEluc3RpdHVjaW9uYWwgZGUgQWNlc3NvIEFiZXJ0byBkYSBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPIENSVVoKcmVzcGVpdGEgb3MgY29udHJhdG9zIGUgYWNvcmRvcyBwcmVleGlzdGVudGVzIGRvcyBBdXRvcmVzIGNvbSB0ZXJjZWlyb3MsIGNhYmVuZG8gYW9zIEF1dG9yZXMKaW5mb3JtYXIgw6AgSW5zdGl0dWnDp8OjbyBhcyBjb25kacOnw7VlcyBlIG91dHJhcyByZXN0cmnDp8O1ZXMgaW1wb3N0YXMgcG9yIGVzdGVzIGluc3RydW1lbnRvcy4KRepositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-10-26T01:22:53Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.pt_BR.fl_str_mv |
Survival benefits of antiretroviral therapy in Brazil: a model-based analysis |
| title |
Survival benefits of antiretroviral therapy in Brazil: a model-based analysis |
| spellingShingle |
Survival benefits of antiretroviral therapy in Brazil: a model-based analysis Luz, Paula M. Brazil HIV Latin America Highly active antiretroviral therapy Modelling Survival |
| title_short |
Survival benefits of antiretroviral therapy in Brazil: a model-based analysis |
| title_full |
Survival benefits of antiretroviral therapy in Brazil: a model-based analysis |
| title_fullStr |
Survival benefits of antiretroviral therapy in Brazil: a model-based analysis |
| title_full_unstemmed |
Survival benefits of antiretroviral therapy in Brazil: a model-based analysis |
| title_sort |
Survival benefits of antiretroviral therapy in Brazil: a model-based analysis |
| author |
Luz, Paula M. |
| author_facet |
Luz, Paula M. Girouard, Michael P. Grinsztejn, Beatriz Freedberg, Kenneth A. Veloso, Valdiléa G. Losina, Elena Struchiner, Claudio J. MacLean, Rachel L. Parker, Robert A. Paltiel, A. David Walensky, Rochelle P. |
| author_role |
author |
| author2 |
Girouard, Michael P. Grinsztejn, Beatriz Freedberg, Kenneth A. Veloso, Valdiléa G. Losina, Elena Struchiner, Claudio J. MacLean, Rachel L. Parker, Robert A. Paltiel, A. David Walensky, Rochelle P. |
| author2_role |
author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Luz, Paula M. Girouard, Michael P. Grinsztejn, Beatriz Freedberg, Kenneth A. Veloso, Valdiléa G. Losina, Elena Struchiner, Claudio J. MacLean, Rachel L. Parker, Robert A. Paltiel, A. David Walensky, Rochelle P. |
| dc.subject.en.pt_BR.fl_str_mv |
Brazil HIV Latin America Highly active antiretroviral therapy Modelling Survival |
| topic |
Brazil HIV Latin America Highly active antiretroviral therapy Modelling Survival |
| description |
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil. |
| publishDate |
2016 |
| dc.date.issued.fl_str_mv |
2016 |
| dc.date.accessioned.fl_str_mv |
2018-10-03T18:48:47Z |
| dc.date.available.fl_str_mv |
2018-10-03T18:48:47Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
LUZ, P. M. et al. Survival benefits of antiretroviral therapy in Brazil: a model-based analysis. Journal of the International AIDS Society, v. 19, n. 1, p. 1-11, 2016. |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/29305 |
| dc.identifier.issn.pt_BR.fl_str_mv |
1758-2652 |
| dc.identifier.doi.none.fl_str_mv |
10.7448/IAS.19.1.20623 |
| identifier_str_mv |
LUZ, P. M. et al. Survival benefits of antiretroviral therapy in Brazil: a model-based analysis. Journal of the International AIDS Society, v. 19, n. 1, p. 1-11, 2016. 1758-2652 10.7448/IAS.19.1.20623 |
| url |
https://www.arca.fiocruz.br/handle/icict/29305 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/29305/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/29305/2/Survival%20benefits%20of%20antiretroviral%20therapy%20in%20Brazil_Paula_Luz_etal_INI_Lapclin-AIDS_2016.pdf https://www.arca.fiocruz.br/bitstream/icict/29305/3/Survival%20benefits%20of%20antiretroviral%20therapy%20in%20Brazil_Paula_Luz_etal_INI_Lapclin-AIDS_2016.pdf.txt |
| bitstream.checksum.fl_str_mv |
586c046dcfeef936e32f0323bb9a47c0 bb72dbf36246c5ce5a3ca14cc9242617 5d6e0cc5c1eb3dd8d4e6d8b7e03b1084 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1813008879674458112 |